Editorial Director, OncLive
Gina Mauro is your lead editorial contact for OncLive. She joined the company in 2015 and has held various positions on OncLive; she is also the on-air correspondent for OncLive News Network: On Location. Prior to joining MJH Life Sciences, she worked at Gannett as a full-time reporter with the Asbury Park Press. Email: gmauro@onclive.com
Johnson Assumes Director Post of Lung Cancer Research at Sarah Cannon Research Institute
January 12th 2021Melissa Johnson, MD, shares her goals for the first 100 days as program director of the Lung Cancer Research at Sarah Cannon Research Institute, the current state of the anti-TIGIT antibody tiragolumab, and the future of lung cancer treatment.
Read More
Phase 2/3 RINGSIDE Trial of AL102 Can Proceed in Desmoid Tumors
January 4th 2021January 4, 2021 — The pivotal phase 2/3 RINGSIDE trial, which is evaluating the potent, selective oral gamma secretase inhibitor AL102, has been permitted to proceed and can potentially be used as a registrational study for adolescent and adult patients with desmoid tumors.
Read More
Treatment with iodine (131I) apamistamab (Iomab-B) conditioning led to a 100% bone marrow transplant rate and engraftment in patients with active relapsed/refractory acute myeloid leukemia who are older than 55 years old, according to results of a single ad hoc interim analysis of the phase 3 SIERRA study.
Read More
ViPOR Regimen Is Safe, Shows Impressive Activity in Relapsed/Refractory DLBCL
December 21st 2020December 21, 2020 — The 5-drug regimen of venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide showed a tolerable safety profile and encouraging antitumor activity with complete responses in patients with relapsed/refractory diffuse large B-cell lymphoma.
Read More
Selinexor Combination Regimens Added to NCCN Guidelines for Multiple Myeloma
December 21st 2020December 21, 2020 - The National Comprehensive Cancer Network has added 3 selinexor combination regimens to its Clinical Practice Guidelines in Oncology for previously treated patients with multiple myeloma.
Read More
Halmos Zeroes in on Year Ahead for Lung Cancer Treatment
December 15th 2020Balazs Halmos, MD discusses the year 2021 and how it will encompass a bigger focus on neoadjuvant and adjuvant trials, more novel molecular compounds for more select subgroups, and a migration of circulating tumor DNA into a more minimal residual disease–based setting.
Read More
Neratinib Improves PFS in HER2+ Breast Cancer With Brain Metastases
December 14th 2020December 14, 2020 - The combination of neratinib and capecitabine showed a 34% reduction in the risk of disease progression or death compared with lapatinib and capecitabine in patients with HER2-positive breast cancer who had central nervous system metastases at baseline.
Read More
Plinabulin/Pegfilgrastim Shows 53% Efficacy Rate in Preventing Profound Neutropenia
December 11th 2020December 11, 2020 - The combination of plinabulin and pegfilgrastim was 53% more effective in reducing the incidence of profound neutropenia compared with pegfilgrastim alone in patients undergoing chemotherapy, according to full findings of the phase 3 PROTECTIVE-2 trial.
Read More
Oncolytic Viral Therapy: A Unique Approach to Explore in GI Cancers
December 11th 2020December 11, 2020 - Oncolytic viral therapy has been heavily investigated across oncology, but plenty of work still lies ahead to determine how this treatment approach can be applied in gastrointestinal malignancies.
Read More
GP2/GM-CSF Combo Elicits 100% DFS Rate in HER2 3+ Breast Cancer at 5 Years
December 11th 2020December 10, 2020 - The GP2 immunotherapy plus granulocyte-macrophage colony-stimulating factor demonstrated potent responses and a 100% disease-free survival in patients with HER2/neu 3–positive disease who received adjuvant trastuzumab.
Read More
Trastuzumab Deruxtecan Continues to Show Impressive Outcomes in HER2+ Metastatic Breast Cancer
December 10th 2020December 10, 2020 - Fam-trastuzumab deruxtecan-nxki continued to showcase impressive signals of efficacy, including prolonged, durable responses and overall survival rates, as well as a tolerable safety profile in patients with HER2-positive metastatic breast cancer.
Read More
Oral Paclitaxel/Encequidar Combo Improves Survival in Metastatic Breast Cancer
December 9th 2020December 9, 2020 - The combination of oral paclitaxel and encequidar led to an estimated 26.5% reduction in the risk of death compared with intravenous paclitaxel in patients with metastatic breast cancer, according to updated phase 3 findings of the KX-ORAX-001 trial.
Read More
Abemaciclib Continues to Show Reduced Risk in iDFS in High-Risk Early HR+ Breast Cancer
December 9th 2020December 9, 2020 - The combination of abemaciclib and standard endocrine therapy showed a 28.7% reduction in the risk of invasive disease recurrence or death compared with endocrine therapy alone in patients with high-risk, early hormone receptor–positive, HER2-negative breast cancer.
Read More
Asciminib Significantly Improves Major Molecular Response in Pretreated Chronic Phase-CML
December 8th 2020Asciminib demonstrated a statistically significant and clinically meaningful improvement in the major molecular response rate at 24 weeks compared with bosutinib in patients with chronic myeloid leukemia in chronic phase who have received at least 2 prior TKIs.
Read More
LOXO-305 Elicits Impressive Responses in Previously Treated CLL/SLL
December 8th 2020LOXO-305, an investigational, highly selective, non-covalent BTK inhibitor, demonstrated an investigator-assessed 63% objective response rate in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.
Read More
Negrin Shines Light on the Orca-T Story in GVHD
December 7th 2020What started out as a journey to better understand regulatory T cells has now led to an intriguing approach with an investigational cell therapy designed to prevent the risk of graft-versus-host disease and to improve relapse-free survival rates in patients undergoing hematopoietic stem cell transplantation.
Read More
December 6, 2020 - Odronextamab, is a novel CD20xCD3 bispecific antibody, continues to show intriguing antitumor activity and an acceptable safety profile in patients with relapsed/refractory B-cell non-Hodgkin lymphoma, including those who have previously received chimeric antigen receptor T-cell therapy.
Read More